BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 32048400)

  • 1. Factors Associated with Endocrine Therapy Non-Adherence in Breast Cancer Survivors.
    Spencer JC; Reeve BB; Troester MA; Wheeler SB
    Psychooncology; 2020 Apr; 29(4):647-654. PubMed ID: 32048400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
    Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG
    J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Racial and Geographic Disparities in Endocrine Therapy Adherence Among Younger Breast Cancer Survivors.
    Heiney SP; Truman S; Babatunde OA; Felder TM; Eberth JM; Crouch E; Wickersham KE; Adams SA
    Am J Clin Oncol; 2020 Jul; 43(7):504-509. PubMed ID: 32251120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine therapy use in the twenty-first century: usage rates and temporal trends illustrate opportunities for improvement for South Carolina Medicaid women.
    Bedi JS; Mayo RM; Truong K; Chen L; Dickes L; Sherrill WW; Jones K
    Breast Cancer Res Treat; 2018 Oct; 171(3):759-765. PubMed ID: 29971626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study.
    Wells KJ; Pan TM; Vázquez-Otero C; Ung D; Ustjanauskas AE; Muñoz D; Laronga C; Roetzheim RG; Goldenstein M; Carrizosa C; Nuhaily S; Johnson K; Norton M; Sims E; Quinn GP
    Support Care Cancer; 2016 Oct; 24(10):4123-30. PubMed ID: 27146492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine Therapy Nonadherence and Discontinuation in Black and White Women.
    Wheeler SB; Spencer J; Pinheiro LC; Murphy CC; Earp JA; Carey L; Olshan A; Tse CK; Bell ME; Weinberger M; Reeder-Hayes KE
    J Natl Cancer Inst; 2019 May; 111(5):498-508. PubMed ID: 30239824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.
    Brier MJ; Chambless DL; Gross R; Chen J; Mao JJ
    Cancer; 2017 Jan; 123(1):169-176. PubMed ID: 27570979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?
    Ekinci E; Nathoo S; Korattyil T; Vadhariya A; Zaghloul HA; Niravath PA; Abughosh SM; Trivedi MV
    J Cancer Surviv; 2018 Jun; 12(3):348-356. PubMed ID: 29396760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.
    Sheppard VB; Sutton AL; Hurtado-de-Mendoza A; He J; Dahman B; Edmonds MC; Hackney MH; Tadesse MG
    Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):699-709. PubMed ID: 33514603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer.
    Walker HE; Rosenberg SM; Stanton AL; Petrie KJ; Partridge AH
    J Adolesc Young Adult Oncol; 2016 Mar; 5(1):16-23. PubMed ID: 26812461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer.
    Rosenberg SM; Zheng Y; Gelber S; Ruddy KJ; Poorvu P; Sella T; Tamimi RM; Wassermann J; Schapira L; Borges VF; Come S; Peppercorn J; Sepucha KR; Partridge AH
    Breast Cancer Res Treat; 2023 Feb; 197(3):547-558. PubMed ID: 36436128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors.
    Emerson MA; Achacoso NS; Benefield HC; Troester MA; Habel LA
    Cancer; 2021 Jun; 127(11):1847-1856. PubMed ID: 33620753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
    Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
    Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
    Farias AJ; Du XL
    J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barriers to endocrine therapy adherence: perspectives of Black breast cancer survivors and their providers.
    Lee KT; Gonzalez BD; Geiss C; Fulton HJ; Charles D; Vadaparampil ST; Henry NL; Jim HSL; Hershman DL; Tworoger SS; Gwede CK
    J Cancer Surviv; 2024 Mar; ():. PubMed ID: 38520598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding Breast Cancer Survivors' Beliefs and Concerns About Adjuvant Hormonal Therapy: Promoting Adherence.
    Hurtado-de-Mendoza A; Jensen RE; Jennings Y; Sheppard VB
    J Cancer Educ; 2018 Apr; 33(2):436-439. PubMed ID: 28205022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facilitators and barriers to medication adherence with adjuvant endocrine therapy in women with breast cancer: a structural equation modelling approach.
    Tan EH; Wong ALA; Tan CC; Wong P; Tan SH; Ang LEY; Lim SE; Chong WQ; Ho J; Lee SC; Tai BC
    Breast Cancer Res Treat; 2021 Aug; 188(3):779-788. PubMed ID: 33948777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer.
    Bright EE; Petrie KJ; Partridge AH; Stanton AL
    Breast Cancer Res Treat; 2016 Jul; 158(2):243-51. PubMed ID: 27342455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer.
    Wassermann J; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Schapira L; Borges VF; Come SE; Meyer ME; Partridge AH
    Cancer; 2019 Sep; 125(18):3266-3274. PubMed ID: 31120571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors.
    Kesmodel SB; Goloubeva OG; Rosenblatt PY; Heiss B; Bellavance EC; Chumsri S; Bao T; Thompson J; Nightingale G; Tait NS; Nichols EM; Feigenberg SJ; Tkaczuk KH
    Am J Clin Oncol; 2018 May; 41(5):508-512. PubMed ID: 27322700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.